

# CCI-001 — Plain-language backgrounder

## The problem

Most chemotherapies attack any rapidly dividing cell, which is why patients suffer hair loss, immune suppression and gastrointestinal toxicity. Modern oncology needs agents that can tell cancer cells apart from healthy ones.

## How CCI-001 is different

Cancer cells overexpress a specific form of tubulin called  $\beta$ III. Healthy somatic tissue does not. CCI-001 is engineered to bind that form selectively, halting cell division in tumors while leaving healthy tissue largely untouched.

## Why it matters

If clinical results match the preclinical and early-phase data, CCI-001 could deliver a wider therapeutic window than existing tubulin inhibitors such as taxanes and vinca alkaloids — potentially enabling earlier-line use, combination regimens, and treatment of patients who cannot tolerate current cytotoxics.

## Where it's being studied first

Bladder cancer is the lead indication, with breast cancer as the next priority. The Phase 1 study is registered as NCT04823897.